France's Telethon is a major event for the LEEM

10 December 2007

The French drug industry association (LEEM) has highlighted the sector's efforts in the search for treatments for rare diseases, on the occasion of the 21st Telethon on French television. The three-day televised fundraising events include a number of initiatives that are supported by the LEEM and its corporate members. Since 2002, the group has incorporated the issue into its strategic action plan. A working party on rare diseases brings together patient associations, health professionals, public and private organizations as well as businesses.

The LEEM also notes that its efforts are not confined to the high-profile event. One of the group's projects is a partnership with the Orphanet to assemble an international reference source for orphan drugs, as well as the core reference point for development opportunities in the areas of rare disease diagnosis and therapy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight